Relief Therapeutics valuation report "Play ACE!" update

Monday, April 10, 2023 @ 12:00 am

Reverse share split proposed at EGM to meet NASDAQ listing criteria. Olpruva US launch in early July. US launches of PKU GOLIKE and Olpruva boost near-term revenue. Successful development of pipeline drugs, including RLF-100 in rare lung disease, RLF-OD032 in PKU, and RLF-TD011 in EB, boost long-term revenue.

Key catalysts include:

US launch of Olpruva in UCDs (early July 2023)
RLF-100 INHALED start of phase IIb sarcoidosis trial (Q2/Q3 2023)
EU filing of Olpruva/ACER-001 in UCDs (H2 2023)

To the full Valuation Report

You may also be interested in

Orio Therapeutics raises CHF 500,000 for cardioprotective therapy development

Orio Therapeutics secures CHF 500,000 pre-seed funding to fuel the development of cardioprotective therapy for heart attack patients.
April 4, 2024

Newron valuation report "A pivotal year"

March 26, 2024

Stämm scales adherent cells by leveraging 3D printing and microfluidics

March 25, 2024

ten23 health: Partnership with SHL Medical

ten23 health, a leading Swiss Contract Development and Manufacturing Organization (CDMO) for sterile drugs, and SHL Medical, a world-leading provider of drug delivery devices, today announced their strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug/device combination products.
March 25, 2024

InSphero unveils promising tool for MASH drug discovery

March 22, 2024

ten23 health's filling line 2 will be GMP operational by end 2024

ten23 health, a leading Swiss contract development and manufacturing organization, today accounced that its VIVA2 aseptic large-scale pre-filled syringe (PFS), vial and cartridge Filling Line 2 will be GMP operational by the end of 2024. Located in Visp, Switzerland, a hub for innovation and excellence in the pharmaceutical sector, VIVA2 will provide state-of-the-art facilities for aseptic manufac
March 18, 2024